AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02374294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiflo
Description: EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.
Study NCT02791308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus Cream 1% (Valeant)
Study NCT02791308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Study NCT02791308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%
Study NCT00111865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
Study NCT03612102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Group Behavioral Treatment (IGBT)
Description: IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
Study NCT01164319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PVI and subcutaneous cardiac monitor implantation
Description: The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Study NCT00271401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00966745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone
Study NCT00966745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04243772 — intervention group
Intervention type: OTHER
Intervention: Data extraction
Description: Data extraction from medical files
Study NCT03757767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting for 26-hours
Description: All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points.
Study NCT03349476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MFAM
Description: Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy
Study NCT01308099 — intervention group
Intervention type: DEVICE
Intervention: Blood Pressure and Blood Flow
Description: A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours.
Study NCT00096278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00166530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
Study NCT00166530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin once daily for 12 weeks. Tablets
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT02545244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Tea
Description: 0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT00096278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02545244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: 0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
Study NCT03796364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Study NCT03796364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard SRILI treatment
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Study NCT03796364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard SRILI treatment
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Study NCT00798837 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intraprostatic maximal simultaneous boost
Description: Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints.
Study NCT02525744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT02525744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog)
Description: Administered SC
Study NCT02122042 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOT
Study NCT02122042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBOT
Study NCT01249794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: continuous positive airways pressure
Study NCT02875444 — intervention group
Intervention type: OTHER
Intervention: Angio-CT
Study NCT02370953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERION for toric IOL alignment
Description: The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
Study NCT02370953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, manual ink-marking for toric IOL alignment
Description: Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
Study NCT04127513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonium Lactate
Description: 12% ammonium lactate moisturizing cream
Study NCT04127513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea
Description: 10% urea moisturizing cream
Study NCT03213379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimetry measures
Description: The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
Study NCT05146479 — intervention group
Intervention type: PROCEDURE
Intervention: Fluoride varnish and pit and fissure sealants onto first permanent molars
Description: Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
Study NCT04421456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
Study NCT04421456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Study NCT02727998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
Study NCT02727998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
Study NCT02545244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Chlorhexidine Mouthwash.
Description: 5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
Study NCT04522986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: 1\*10\^8 cells are administered once a week, total four times intravenously.
Study NCT04450758 — intervention group
Intervention type: PROCEDURE
Intervention: Bridge to Surgery (stent or stoma)
Description: The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
Study NCT02188810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAL
Description: Single dose administered intramuscularly.
Study NCT04047472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6mg
Description: Intravitreal injection
Study NCT04047472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Intravitreal injection
Study NCT02075892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mushroom Blend
Description: Scivation
Study NCT02075892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04715971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: portable ultrasound bladder scan
Description: A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
Study NCT04356352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
Study NCT02502266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02502266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02502266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02502266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02502266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02502266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV
Study NCT02502266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01716013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BondEase
Description: topical skin adhesive
Study NCT01716013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CWCD
Description: traditional closure methods of sutures, staples or adhesive strips
Study NCT04409288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Androgen receptor inhibitor.
Study NCT04409288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Androgern receptor inhibitor
Study NCT03318991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser prostatectomy
Description: Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
Study NCT00771433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT05256121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD Risk factors balance
Description: At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback.
Study NCT02188810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: Single dose administered intramuscularly .
Study NCT04113499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Endoscopic Intervention
Description: The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes.
Study NCT04113499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up Endoscopic Intervention
Description: The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention).
Study NCT01138280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CWP 103H (Gambro, Sweden): a heat disinfection device
Description: Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
Study NCT03090100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
Study NCT03090100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
Study NCT03090100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Study NCT03209492 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuplin PRO for Injection Kit 22.5 mg
Study NCT02188810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Single dose administered intramuscularly .
Study NCT01889147 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hRESCAP
Description: one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
Study NCT01889147 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03857815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks.
Study NCT01259271 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Selective Nerve Stimulation (SNS) stimulator device
Description: Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
Study NCT01259271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Nerve Stimulation (SNS) stimulator device
Description: Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
Study NCT03536741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block and RS block + General Intravenous Anesthestic
Description: transversus abdominis plane block and rectus sheath block